Which has higher earnings & valuation, BCAB or FLGC?

Flora Growth has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $2M 2.70 -$59.61M -$41.72 N/A Flora Growth $57.61M 0.03 -$15.91M -$32.49 N/A

Is BCAB or FLGC more profitable?

BioAtla has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. BioAtla's return on equity of 0.00% beat Flora Growth's return on equity. Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Flora Growth -32.03% -64.02% -34.46%

Do analysts recommend FLGC or INM?

Flora Growth presently has a consensus price target of $30.00, suggesting a potential upside of 1,873.68%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts clearly believe Flora Growth is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend FLGC or XBIO?

Flora Growth currently has a consensus price target of $30.00, suggesting a potential upside of 1,873.68%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Xenetic Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CURX or FLGC?

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 1,873.68%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts clearly believe Flora Growth is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Flora Growth 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Flora Growth (FLGC) Competitors

$1.52 -0.02 (-1.30%)

As of 07/31/2026

Compare

FLGC vs. BCAB, INM, RVPH, XBIO, and CURX

Should you buy Flora Growth stock or one of its competitors? MarketBeat compares Flora Growth with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Flora Growth include BioAtla (BCAB), InMed Pharmaceuticals (INM), Reviva Pharmaceuticals (RVPH), Xenetic Biosciences (XBIO), and Curanex Pharmaceuticals (CURX).

How does Flora Growth compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Flora Growth (NASDAQ:FLGC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 6,027.45%. Flora Growth has a consensus price target of $30.00, indicating a potential upside of 1,873.68%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Flora Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Flora Growth has higher revenue and earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	2.70	-$59.61M	-$41.72	N/A
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A

In the previous week, BioAtla's average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
Flora Growth	Neutral

77.2% of BioAtla shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BioAtla has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

BioAtla has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. BioAtla's return on equity of 0.00% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Flora Growth	-32.03%	-64.02%	-34.46%

Summary

BioAtla and Flora Growth tied by winning 6 of the 12 factors compared between the two stocks.

How does Flora Growth compare to InMed Pharmaceuticals?

Flora Growth (NASDAQ:FLGC) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

InMed Pharmaceuticals has lower revenue, but higher earnings than Flora Growth. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A
InMed Pharmaceuticals	$4.94M	0.98	-$8.16M	-$2.89	N/A

Flora Growth has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

36.0% of Flora Growth shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 2.3% of Flora Growth shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Flora Growth's average media sentiment score of 0.00 equaled InMed Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Flora Growth	Neutral
InMed Pharmaceuticals	Neutral

Flora Growth presently has a consensus price target of $30.00, suggesting a potential upside of 1,873.68%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts clearly believe Flora Growth is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Flora Growth has a net margin of -32.03% compared to InMed Pharmaceuticals' net margin of -132.87%. Flora Growth's return on equity of -64.02% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%

Summary

Flora Growth beats InMed Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Reviva Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Flora Growth (NASDAQ:FLGC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Reviva Pharmaceuticals' average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company	Overall Sentiment
Reviva Pharmaceuticals	Neutral
Flora Growth	Neutral

Flora Growth has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Reviva Pharmaceuticals	N/A	N/A	-$19.86M	-$4.06	N/A
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A

Reviva Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 16,512.68%. Flora Growth has a consensus price target of $30.00, indicating a potential upside of 1,873.68%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Flora Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Reviva Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Reviva Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Reviva Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Reviva Pharmaceuticals	N/A	-391.58%	-119.08%
Flora Growth	-32.03%	-64.02%	-34.46%

Reviva Pharmaceuticals has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Flora Growth has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

Summary

Reviva Pharmaceuticals beats Flora Growth on 7 of the 13 factors compared between the two stocks.

How does Flora Growth compare to Xenetic Biosciences?

Flora Growth (NASDAQ:FLGC) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Flora Growth currently has a consensus price target of $30.00, suggesting a potential upside of 1,873.68%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Xenetic Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Flora Growth's average media sentiment score of 0.00 equaled Xenetic Biosciences'average media sentiment score.

Company	Overall Sentiment
Flora Growth	Neutral
Xenetic Biosciences	Neutral

Flora Growth has a net margin of -32.03% compared to Xenetic Biosciences' net margin of -70.03%. Xenetic Biosciences' return on equity of -39.28% beat Flora Growth's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Xenetic Biosciences	-70.03%	-39.28%	-33.47%

Flora Growth has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.1, suggesting that its stock price is 110% more volatile than the broader market.

Xenetic Biosciences has lower revenue, but higher earnings than Flora Growth. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A
Xenetic Biosciences	$2.98M	2.01	-$2.68M	-$1.20	N/A

36.0% of Flora Growth shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Flora Growth and Xenetic Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Flora Growth compare to Curanex Pharmaceuticals?

Curanex Pharmaceuticals (NASDAQ:CURX) and Flora Growth (NASDAQ:FLGC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Curanex Pharmaceuticals has higher earnings, but lower revenue than Flora Growth. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Flora Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$0.27	N/A
Flora Growth	$57.61M	0.03	-$15.91M	-$32.49	N/A

In the previous week, Curanex Pharmaceuticals' average media sentiment score of 0.00 equaled Flora Growth'saverage media sentiment score.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
Flora Growth	Neutral

Curanex Pharmaceuticals has a net margin of 0.00% compared to Flora Growth's net margin of -32.03%. Flora Growth's return on equity of -64.02% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-85.41%	-82.11%
Flora Growth	-32.03%	-64.02%	-34.46%

36.0% of Flora Growth shares are owned by institutional investors. 39.7% of Curanex Pharmaceuticals shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Flora Growth has a consensus target price of $30.00, indicating a potential upside of 1,873.68%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts clearly believe Flora Growth is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flora Growth	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Flora Growth beats Curanex Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get Flora Growth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLGC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLGC vs. The Competition

Export

Metric	Flora Growth	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.59M	$5.72B	$6.81B	$12.55B
Dividend Yield	N/A	1.79%	2.59%	10.03%
P/E Ratio	-0.05	23.62	282.12	24.83
Price / Sales	0.03	57.68	573.08	78.59
Price / Cash	N/A	32.53	28.60	46.71
Price / Book	0.12	6.43	11.02	6.15
Net Income	-$15.91M	$151.15M	$3.49B	$347.61M
7 Day Performance	4.83%	2.70%	0.47%	1.17%
1 Month Performance	-54.63%	-1.83%	-4.24%	-3.46%
1 Year Performance	-92.36%	4.26%	62.63%	19.43%

Flora Growth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLGC Flora Growth	N/A	$1.52 -1.3%	$30.00 +1,873.7%	-92.4%	$1.59M	$57.61M	N/A	280
BCAB BioAtla	1.7936 of 5 stars	$3.39 -4.1%	$200.00 +5,808.4%	-80.1%	$5.62M	$2M	N/A	60	Upcoming Earnings Gap Up
INM InMed Pharmaceuticals	1.2171 of 5 stars	$1.66 -0.4%	N/A	-38.5%	$5.51M	$4.94M	N/A	10
RVPH Reviva Pharmaceuticals	1.6671 of 5 stars	$0.42 -0.6%	$66.67 +15,773.0%	-95.0%	$5.51M	N/A	N/A	5
XBIO Xenetic Biosciences	0.7151 of 5 stars	$2.40 -4.2%	N/A	-20.6%	$5.49M	$2.98M	N/A	4	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLGC) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Flora Growth (FLGC) Competitors

FLGC vs. BCAB, INM, RVPH, XBIO, and CURX

How does Flora Growth compare to BioAtla?

Summary

How does Flora Growth compare to InMed Pharmaceuticals?

Summary

How does Flora Growth compare to Reviva Pharmaceuticals?

Summary

How does Flora Growth compare to Xenetic Biosciences?

Summary

How does Flora Growth compare to Curanex Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Flora Growth (FLGC) Competitors

FLGC vs. BCAB, INM, RVPH, XBIO, and CURX

How does Flora Growth compare to BioAtla?

Do analysts recommend BCAB or FLGC?

Which has higher earnings & valuation, BCAB or FLGC?

Does the media prefer BCAB or FLGC?

Do institutionals & insiders believe in BCAB or FLGC?

Which has more risk and volatility, BCAB or FLGC?

Is BCAB or FLGC more profitable?

Summary

How does Flora Growth compare to InMed Pharmaceuticals?

Which has preferable earnings and valuation, FLGC or INM?

Which has more risk & volatility, FLGC or INM?

Do institutionals & insiders have more ownership in FLGC or INM?

Does the media favor FLGC or INM?

Do analysts recommend FLGC or INM?

Is FLGC or INM more profitable?

Summary

How does Flora Growth compare to Reviva Pharmaceuticals?

Do institutionals & insiders believe in RVPH or FLGC?

Does the media favor RVPH or FLGC?

Which has stronger valuation & earnings, RVPH or FLGC?

Do analysts rate RVPH or FLGC?

Is RVPH or FLGC more profitable?

Which has more risk and volatility, RVPH or FLGC?

Summary

How does Flora Growth compare to Xenetic Biosciences?

Do analysts recommend FLGC or XBIO?

Does the media refer more to FLGC or XBIO?

Is FLGC or XBIO more profitable?

Which has more volatility & risk, FLGC or XBIO?

Which has higher valuation & earnings, FLGC or XBIO?

Do insiders & institutionals hold more shares of FLGC or XBIO?

Summary

How does Flora Growth compare to Curanex Pharmaceuticals?

Which has better earnings and valuation, CURX or FLGC?

Does the media favor CURX or FLGC?

Is CURX or FLGC more profitable?

Do insiders & institutionals believe in CURX or FLGC?

Do analysts prefer CURX or FLGC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLGC vs. The Competition

Flora Growth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools